title: Antiadenoviral effect of the alpha 5 beta 1 integrin receptor ligand, GRGDSP peptide, in serotypes that cause acute keratoconjunctivitis.
abstract: OBJECTIVE
  In adenoviral conjunctivitis, the infection process starts by the attachment of adenoviral fibers to conjunctival epithelial cells that contain the receptor for the adenovirus. The alpha 5 beta 1 integrin receptor ligand, GRGDSP peptide, contains the arginine-glycine-aspartate-binding motif which is common to the Coxsackie adenovirus receptor and integrins that are known to be adenoviral receptors. We evaluated the antiadenoviral effect of an expected adenoviral receptor inhibitor, GRGDSP peptide,in vitro.
  
  
  METHODS
  Adenovirus types 3, 4, 8, 19 and 37 were used. After calculating the 50% cytotoxic concentration of GRGDSP peptide, the adenovirus was cultivated with the agent for 7 days under serial dilution. Adenoviral DNA was qualitatively measured by real-time PCR.
  
  
  RESULTS
  GRGDSP peptide showed an inhibitory effect against adenoviral proliferation in all serotypes except type 4 in a dose-dependent manner.
  
  
  CONCLUSIONS
  This result suggests that the alpha 5 beta 1 integrin receptor ligand, GRGDSP peptide, has antiadenoviral activity in vitro, and the possibility of being used for local treatment of epidemic keratoconjunctivitis.
authors.affiliation: Department of Ophthalmology, Fukuoka University School of Medicine, Fukuoka, Japan. euchio@fukuoka-u.ac.jp
authors.forename: Eiichi
authors.initials: E
authors.lastname: Uchio
authors.forename: Ryoji
authors.initials: R
authors.lastname: Kimura
authors.forename: Yuh-Huey
authors.initials: YH
authors.lastname: Huang
authors.forename: Aya
authors.initials: A
authors.lastname: Fuchigami
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Kadonosono
authors.forename: Akio
authors.initials: A
authors.lastname: Hayashi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ishiko
authors.forename: Koki
authors.initials: K
authors.lastname: Aoki
authors.forename: Shigeaki
authors.initials: S
authors.lastname: Ohno
mesh_terms: D000208:Acute Disease; D000256:Adenoviridae / Q000145:classification / Q000187:drug effects* / Q000472:pathogenicity; D000257:Adenoviridae Infections; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D006801:Humans; D039081:Integrin alpha5beta1 / Q000378:metabolism*; D007637:Keratoconjunctivitis / Q000821:virology*; D008024:Ligands; D009842:Oligopeptides / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology*; D012703:Serotyping; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D039081:Integrin alpha5beta1; D008024:Ligands; D009842:Oligopeptides; C058161:glycyl-arginyl-glycyl-aspartyl-seryl-proline